XNYSBIO.B
Market cap9.26bUSD
Dec 18, Last price
325.85USD
Name
Bio Rad Laboratories Inc
Chart & Performance
Profile
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 2,671,262 -4.67% | 2,802,249 -4.12% | 2,922,545 14.81% | |||||||
Cost of revenue | 1,466,843 | 1,491,808 | 1,553,541 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 1,204,419 | 1,310,441 | 1,369,004 | |||||||
NOPBT Margin | 45.09% | 46.76% | 46.84% | |||||||
Operating Taxes | (212,780) | (1,076,738) | 1,192,247 | |||||||
Tax Rate | 87.09% | |||||||||
NOPAT | 1,417,199 | 2,387,179 | 176,757 | |||||||
Net income | (637,324) -82.43% | (3,627,535) -185.27% | 4,254,257 11.54% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (428,728) | 69,370,220 | 35,232,002 | |||||||
BB yield | 4.55% | -553.89% | -154.36% | |||||||
Debt | ||||||||||
Debt current | 40,379 | 465 | 489 | |||||||
Long-term debt | 1,560,787 | 1,387,649 | 233,887 | |||||||
Deferred revenue | 9,648 | 1,770,481,000 | (3,059,080) | |||||||
Other long-term liabilities | 204,713 | (1,770,131,491) | 3,417,209 | |||||||
Net debt | (7,702,546) | (9,239,010) | (15,028,108) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 374,943 | 194,447 | 656,521 | |||||||
CAPEX | (156,680) | (114,157) | (120,803) | |||||||
Cash from investing activities | 20,208 | (1,207,593) | (784,438) | |||||||
Cash from financing activities | (425,647) | 973,576 | (55,429) | |||||||
FCF | 1,172,000 | 2,043,025 | 254,772 | |||||||
Balance | ||||||||||
Cash | 1,607,142 | 1,796,232 | 875,478 | |||||||
Long term investments | 7,696,570 | 8,830,892 | 14,387,006 | |||||||
Excess cash | 9,170,149 | 10,487,012 | 15,116,357 | |||||||
Stockholders' equity | 8,924,594 | 9,431,384 | 13,331,691 | |||||||
Invested Capital | 1,416,561 | 1,699,130 | 658,276 | |||||||
ROIC | 90.97% | 202.53% | 26.85% | |||||||
ROCE | 10.19% | 10.16% | 8.03% | |||||||
EV | ||||||||||
Common stock shares outstanding | 29,209 | 29,785 | 30,208 | |||||||
Price | 322.89 -23.21% | 420.49 -44.35% | 755.57 29.61% | |||||||
Market cap | 9,431,294 -24.70% | 12,524,295 -45.13% | 22,824,259 29.82% | |||||||
EV | 1,728,748 | 3,285,285 | 7,796,151 | |||||||
EBITDA | 1,204,419 | 1,447,737 | 1,502,805 | |||||||
EV/EBITDA | 1.44 | 2.27 | 5.19 | |||||||
Interest | 49,439 | 38,114 | 1,551 | |||||||
Interest/NOPBT | 4.10% | 2.91% | 0.11% |